Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer

BACKGROUND: Agents blocking programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) have been approved for triple-negative breast cancer (TNBC). However, the response rate of anti-PD-1/PD-L1 is still unsatisfactory, partly due to immunosuppressive factors such as transforming growth f...

Descripción completa

Detalles Bibliográficos
Autores principales: Yi, Ming, Wu, Yuze, Niu, Mengke, Zhu, Shuangli, Zhang, Jing, Yan, Yongxiang, Zhou, Pengfei, Dai, Zhijun, Wu, Kongming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9723957/
https://www.ncbi.nlm.nih.gov/pubmed/36460337
http://dx.doi.org/10.1136/jitc-2022-005543

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9723957/
https://www.ncbi.nlm.nih.gov/pubmed/36460337
http://dx.doi.org/10.1136/jitc-2022-005543

Ejemplares similares